When Will Semaglutide Go Generic in the UK?

What the patent data actually shows about semaglutide's generic timeline

The question of when semaglutide will go generic is largely a patent question, and the answer is more complicated than a single expiry date. Novo Nordisk holds a cluster of patents on semaglutide: the original compound patent, formulation patents covering how the drug is stabilised and administered, and device patents covering the auto-injector pen. In the United States, primary compound patents on semaglutide run into the early 2030s; UK and European equivalents follow a broadly similar schedule, though exact expiry dates differ by jurisdiction and some have supplementary protection certificates that extend protection further.

A reasonable working assumption, based on publicly available patent filings and pharmaceutical industry precedent, is that the earliest any biosimilar semaglutide could reach UK patients is mid-to-late 2030s, and that assumes a competitor files early, completes clinical development on schedule, and gains MHRA approval without delays. Some analysts point to 2031–2032 as a plausible US biosimilar entry window, with other markets following later. The more detailed breakdown of specific filing dates is covered on our semaglutide patent expiry page. The short version: this is a long runway, not an imminent change.

For UK patients, the practical implication is straightforward. If you are waiting for a cheaper generic before starting treatment, you are likely looking at a decade-long wait during which your health situation continues unchanged. Current Wegovy prescribing operates within an established, MHRA-licensed framework that exists right now.

Why 'generic semaglutide' is the wrong term, biosimilars explained

Semaglutide is not a small chemical molecule you can synthesise identically in a generic laboratory. It is a large, complex peptide, a GLP-1 analogue with a fatty acid chain that gives it its once-weekly action. Manufacturing it requires biological processes, not simple chemical synthesis. That distinction is why the pharmaceutical industry uses the term biosimilar rather than generic: a biosimilar is a highly similar (but not atom-for-atom identical) version of a biological medicine, demonstrated through its own clinical evidence to be as safe and effective as the original.

The regulatory hurdle is substantially higher than for small-molecule generics. A biosimilar manufacturer must conduct comparative clinical trials and analytical studies, then submit a full dossier to the MHRA for approval. This is not a shortcut, it is a separate development programme that takes years and costs hundreds of millions of pounds. The biosimilar and generic semaglutide landscape page covers the regulatory pathway in more detail. For now, the only semaglutide products licensed in the UK for weight management are Wegovy (injection and, from June 2026, tablets), both made by Novo Nordisk.

Ozempic, also semaglutide and also made by Novo Nordisk, is licensed solely for type 2 diabetes in the UK; the differences between these branded versions matter more than their shared active ingredient.

What the evidence says about the medicines available today

While the generic question has no near-term answer, the evidence base for the currently licensed medicines is substantial. The STEP 1 trial, published in the New England Journal of Medicine, found that adults with obesity using semaglutide 2.4mg weekly lost an average of around 15% of their body weight over 68 weeks alongside lifestyle changes. The OASIS 4 phase 3 trial, which supported the June 2026 MHRA approval of the Wegovy tablet, reported around 13.6% average weight loss over 64 weeks, rising to approximately 16.6% among participants who fully adhered to treatment and lifestyle guidance.

NICE recommends semaglutide (Wegovy) for eligible adults under technology appraisal TA875, though the NHS criteria involve specialist weight management services and specific BMI and comorbidity thresholds, with waiting lists that can be long. Private prescribing operates under the same clinical standards but without the waiting. On the cost side, treatment pricing and what's included is shown clearly on our treatments page, worth checking if you want a like-for-like picture of what private prescribing actually costs today versus the indefinite wait for a semaglutide generic that may arrive a decade from now.

One practical habit worth building: you can verify any UK online pharmacy's registration status in under a minute using the GPhC pharmacy register. If a website offering semaglutide is not listed there, that is a serious red flag regardless of how low the price looks.

The UK regulatory picture and what it means for future availability

Even if a biosimilar semaglutide were approved tomorrow, it would enter the UK market as a prescription-only medicine requiring the same clinical pathway as the branded version: a prescriber's assessment, a valid prescription, and dispensing through a GPhC-registered pharmacy. Patent expiry does not change the Human Medicines Regulations. It changes who can manufacture the medicine and, over time, what competition does to pricing, but the clinical gate stays in place.

The MHRA licenses medicines for UK use independently of the EMA, so European biosimilar approvals do not automatically apply here. Any manufacturer seeking UK access must either use the post-Brexit MHRA assessment route or apply for a Great Britain licence separately. That adds regulatory lead time on top of the development timeline already described.

Our clinical team keeps pace with MHRA announcements and NICE guidance changes; if the competitive landscape shifts meaningfully, that feeds directly into how we support patients. For anyone considering treatment now, the question is less about when a generic might arrive and more about what clinically supervised, licensed treatment looks like today. If you want to explore that, a free consultation with our prescribers is the straightforward next step.